MOLECULAR PARTNERS PARTICIPATES TODAY IN FIRESIDE CHAT AT THE MORGAN STANLEY GLOBAL HEALTHCHARE CONFERENCE IN NEW YORK Mittwoch, 12. September 2018 - 17:31
| Media Release (PDF) | ||||||||||||||
MOLECULAR PARTNERS PARTICIPATES TODAY IN FIRESIDE CHAT | ||||||||||||||
Zurich-Schlieren, September 12, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics to treat serious diseases, announces that Dr. Patrick Amstutz, CEO and Andreas Emmenegger, CFO of Molecular Partners will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference today, September 12, 2018 at 5:25 PM Eastern Time (11:25 PM CET).
The presentation will be available for viewing via live webcast and can be accessed on the day through this link. A replay of the webcast will be made available on the company's website www.molecularpartners.com under the Investors section. The replay will be available for 180 days following the presentation. | ||||||||||||||
About Molecular Partners AG Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapeutics. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on oncology and immuno-oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.
For more information regarding Molecular Partners AG, go to: www.molecularpartners.com.
For further details, please contact:
|